Topic archive

psychedelic research

11 stories

8/21/2026

Johnson & Johnson invests in Delix Therapeutics

Investment in neuroplastogen company highlights growing interest in non-hallucinogenic psychedelics.

8/21/2026

Trump administration accelerates psychedelic research for veterans' mental health.

8/19/2026

U.S. backing could accelerate ibogaine research for mental health.

8/19/2026

Market optimism grows as Psyence Biomedical advances ibogaine studies.

8/19/2026

Former President Trump supports ibogaine research, sparking industry response.

8/10/2026

Arizona funds first U.S. ibogaine trial for traumatic brain injuries, starting 2027.

8/10/2026

ARPA-H seeks to accelerate ibogaine trials for opioid treatment

7/29/2026

Psychedelic trials often exclude marginalized groups, raising questions about equity and efficacy.

7/29/2026

State-led ibogaine study in Texas gains federal backing, marking a significant research development.

7/24/2026

Psychoactive drug ibogaine gains attention for addiction treatment potential.

7/17/2026

Pharmaceutical giant expands into psychedelic research with major acquisition.